INTEGUMENTARY SYSTEM

Published on 19/03/2015 by admin

Filed under Pathology

Last modified 19/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 2 (1 votes)

This article have been viewed 4049 times

11 INTEGUMENTARY SYSTEM

The integument is the largest organ of the body. It consists of two components: (1) the skin and (2) the epidermal derivatives, such as nails, hair, and glands (sweat and sebaceous glands and the mammary gland).

The skin is of particular significance in a clinical physical examination. For example, the color of the skin may indicate the existence of a pathologic condition: a yellow color indicates jaundice; a blue-gray color may indicate cyanosis, reflecting a pathologic condition of cardiovascular and respiratory function; a pale color is indicative of anemia; lack of skin pigmentation suggests albinism, a genetic trait characterized by lack of the enzyme tyrosinase, involved in the conversion of the amino acid tyrosine to melanin. Many infectious and immunologic diseases produce characteristic skin changes leading to a correct diagnosis. In addition, the skin has diseases peculiar to itself.

The skin has several functions: (1) protection (mechanical function); (2) as a water barrier; (3) regulation of body temperature (conservation and dissipation of heat); (4) nonspecific defense (barrier to microorganisms); (5) excretion of salts; (6) synthesis of vitamin D; (7) as a sensory organ; and (8) sexual signaling.

General organization and types of skin

The skin consists of three layers firmly attached to one another (Figure 11-1): (1) the outer epidermis—derived from ectoderm; (2) the deeper dermis—derived from mesoderm; and (3) the hypodermis or subcutaneous layer—corresponding to the superficial fascia of gross anatomy.

Skin is generally classified into two types: (1) thick skin and (2) thin skin.

Thick skin (more than 5 mm thick) covers the palms of the hands and the soles of the feet and has a thick epidermis and dermis. Thin skin (1 to 2 mm in thickness) lines the rest of the body; the epidermis is thin.

The surface of the skin of the palms and soles and digits of the hands and feet has narrow epidermal ridges separated by furrows. Each epidermal ridge corresponds to an underlying dermal papilla. Ridges and papillae are permanent, have a constant pattern, and are unique to each individual. Impressions of the ridges create fingerprint patterns, useful for forensic identification.

The epidermis and dermis display a tight fit interface at the dermal-epidermal junction, where a basal lamina and hemidesmosomes are located. A primary epidermal ridge interlocks with a subjacent primary dermal ridge (see Figure 11-1). An epidermal interpapillary peg, projecting downward from the primary epidermal ridge, interlocks with the primary dermal ridge, which is subdivided into two secondary dermal ridges. A number of dermal papillae project upward from the surface of each secondary dermal ridge into the epidermal region, interlocking with downward projections of the epidermis. This arrangement is predominant in hairless thick skin. Dermal papillae are numerous and branched. In thin skin, papillae are low and their number is reduced.

EPIDERMIS

The stratified squamous epithelial layer of the epidermis consists of four distinct cell types (Figure 11-2):

Keratinocytes are arranged in five layers or strata: (1) the stratum basale (basal cell layer); (2) the stratum spinosum (spinous or prickle cell layer); (3) the stratum granulosum (granular cell layer); (4) the stratum lucidum (clear cell layer); and (5) the stratum corneum (cornified cell layer). The first cell layers consist of metabolically active cells; cells of the last two layers undergo keratinization, or cornification, a process that involves cellular and intercellular molecular changes.

Both the stratum basale and stratum spinosum form the stratum of Malpighi. The stratum basale (or stratum germinativum) consists of a single layer of columnar or high cuboidal keratinocytes resting on a basement membrane. The cytoplasm contains intermediate filaments associated with desmosomes. Bundles of intermediate filaments, visible under the light microscope, are called tonofilaments. Hemidesmosomes and associated intermediate filaments anchor the basal domain of basal cells to the basement membrane.

The cells of the stratum basale undergo mitosis. While some of the dividing cells add to the population of stem cells of the stratum basale, others migrate into the stratum spinosum to initiate the differentiation process, ending with the formation of the stratum corneum.

Clinical significance: Wound healing

Skin is an efficient protective barrier. If a portion of epidermis is damaged or destroyed, it must be repaired rapidly by a sequential mechanism called wound healing. This mechanism consists of four stages: (1) the formation of a fibrin-platelet clot; (2) leukocyte recruitment; (3) neovascularization and cellular proliferation; and (4) tissue remodeling.

Wound healing starts with the formation of a blood clot covering temporarily the open wound. We discussed in Chapter 6, Blood and Hematopoiesis, that the blood clot consists of platelets embedded in a fibrous mesh of cross-linked fibrin molecules formed when thrombin cleaves fibrinogen.

We discussed in Chapter 6 that platelets contain platelet-derived growth factor (PDGF) stored in alpha granules. PDGF and other growth factors are released when platelets degranulate and leukocytes arrive at the wound site. Keratinocytes and endothelial cells express cytokine CXC (for cysteine-x-cysteine) and CXC receptor, which recruit neutrophils, monocytes, and lymphocytes to the wound site. A deletion of CXC receptor gene results in delayed wound healing.

Neutrophils arrive within minutes of injury and release proinflammatory cytokines to activate local fibroblasts in the dermis and keratinocytes in the epidermis. Monocytes are recruited next and become macrophages, which produce cytokines, growth factors, and angiogenic factors. New blood vessels develop (angiogenic response) and organize granulation tissue. The pink granular appearance of the granulation tissue is determined by the formation of numerous blood capillaries.

Reepithelialization starts when keratinocytes of the stratum basale layer migrate from the edges of the wound by the formation of F-actin–containing lamellopodia. We discuss in Chapter 1, Epithelium, that hemidesmosomes anchor basal cells to the basal lamina. Leading edge keratinocytes facilitate their displacement by disrupting hemidesmosome attachment to the basal lamina and by dissolving the fibrin clot barrier. To accomplish the dissolution of the fibrin clot, keratinocytes up-regulate the expression of plasminogen activator to convert plasminogen within the clot into the fibrinolytic enzyme plasmin. Keratinocytes become free from hemidesmosome anchorage with the help of members of the matrix metalloproteinase family produced by fibroblasts in the dermis. We discussed the importance of matrix metalloproteinases in Chapter 4, Connective Tissue.

Members of the epidermal growth factor family (including epidermal growth factor, transforming growth factor-α, and heparin binding epidermal growth factor) and keratinocyte growth factor drive re-epithelialization. After the wound surface has been covered by a monolayer of keratinocytes, a new stratified squamous epithelium is established from the margin of the wound toward the center. New hemidesmosomes are formed with the inactivation of matrix metalloproteinases.

Within 3 to 4 days after the wound injury, the underlying connective tissue of the dermis contracts, bringing the wound margins toward one another. Stimulated by local levels of PDGF and transforming growth factor-β, dermal fibroblasts begin to proliferate, infiltrate the blood clot, and deposit type III collagen and extracellular matrix. About 1 week after wounding, a number of wound fibroblasts change into myofibroblasts (resembling smooth muscle cells), wound contraction takes place, and healing with a scar occurs.

Retinol (vitamin A) is a precursor of retinoic acid, a hormone-like agent required for the differentiation of epithelia, including epidermis. Retinoids have a proliferative effect on the epidermis of normal skin. This effect is mediated at the messenger RNA (mRNA) level by inhibiting cell differentiation and stimulating cell proliferation.

Retinoic acid binds to cellular retinoic acid binding (CRAB) proteins, presumably involved in the regulation of the intracellular concentration of retinoic acid. Similar to steroid and thyroid hormones, retinoic acid binds to two types of nuclear receptors: retinoic acid receptors (RARs), and rexinoid receptors (RXRs).

The RAR/RXR heterodimer complex has binding affinity for retinoic acid–responsive elements (RAREs) on DNA and controls the expression of retinoic acid responsive genes. Retinoids are used in the prevention of acne scarring, psoriasis, and other scaling diseases of the skin.

Clinical significance: Psoriasis

Psoriasis is an inflammatory skin disorder. It is characterized by sharply demarcated plaques, called psoriatic plaques, covered by white scales commonly seen on the elbows, knees, scalp, umbilicus, and lumbar region. Physical trauma may produce psoriatic plaques at the sites of injury.

The histologic characteristics of the psoriatic plaque include excessive proliferation of epidermal keratinocytes (caused by an accelerated migration of keratinocytes from the stratum basale to the stratum corneum), presence of inflammatory cells (T cells and neutrophils) in the dermis and epidermis (microabscesses), elongation of epidermic papillae, and prominent angiogenesis (Figure 11-4).

Langerhans cells initiate the psoriatic process. The role of Langerhans cells in the activation of T cells in regional lymph nodes is summarized in Figure 11-4.

Cytokines play a significant role in the trafficking and distribution of T cells in the psoriatic skin. Effector T cells are characterized by the expression of the skin homing receptor cutaneous lymphocyte-associated (CLA) antigen and CD45. CD45+ CLA+ T cells arrive at sites of cutaneous inflammation, secrete proinflammatory cytokines, and produce the psoriatic plaques. Treatment of psoriasis is targeted to the therapeutic inhibition of T cell activation (determined by Langerhans cells in the lymph node), depletion of activated T cells (by monoclonal antibodies directed to cell surface molecules expressed by Langerhans cell–activated T cells), and preventing the recruitment of CD45+ CLA+ T cells (by monoclonal antibodies blocking specific homing).

Differentiation of a keratinocyte

Keratinocytes of the stratum spinosum have a flattened polygonal shape with a distinct ovoid nucleus. The cytoplasm displays small granules with a lamellar core, called membrane-coating granules, or lamellar bodies. Bundles of intermediate filaments—tonofibrils—extend into the cytoplasmic spinous-like processes and attach to the dense plaque of a desmosome.

The stratum granulosum consists of a multilayered assembly of flattened nucleated keratinocytes with characteristic, irregularly shaped keratohyalin granules without a limiting membrane and associated with the tonofilaments. The lamellar bodies, which first appear in keratinocytes of the stratum spinosum, increase in number in the stratum granulosum, and the lamellar product, the glycolipid acylglucosylceramide, is released into the intercellular spaces (Figure 11-5). Tight junctions, containing claudin-1 and claudin-4, are found in the stratum granulosum (Figure 11-6). In the intercellular space, the lamellar lipid material forms a multilayered structure arranged in wide sheets, coating the surface of keratinocytes of the upper layer, the stratum lucidum. The glycolipid coating provides the water barrier of the epidermis.

The stratum lucidum is recognized by some histologists as an intermediate layer above the stratum granulosum and beneath the stratum corneum. However, no distinctive cytologic features are significantly apparent.

Both the stratum lucidum and stratum corneum consist of several layers of keratinocytes without nuclei and a cytoplasm containing aggregated intermediate filaments of keratin cross-linked with filaggrin (see Figure 11-6) by a process catalyzed by transglutaminases. Filaggrin aggregates keratin intermediate filaments into tight bundles, leading to cell flattening, a characteristic of the stratum corneum.

The keratin-filaggrin complex is deposited on the inside of the plasma membrane forming a structure called the cornified cell envelope (Figure 11-7). Additional proteins—involucrin, small proline–rich proteins (SPRs), and loricrin—are cross-linked by several transglutaminases and reinforce the cornified cell envelope just beneath the plasma membrane. On the outside of the cell, a complex of lipids extruded from lamellar bodies cross-link the cell envelope, forming the compound cornified cell envelope.

In summary, keratinocytes of the stratum corneum consist of a keratin-filaggrin matrix surrounded by a reinforcing involucrin–SPRs–loricrin complex that provides elasticity and mechanical resistance. Extracellular insoluble lipids, cross-linked to involucrin, make the cell membrane impermeable to fluids (permeability barrier). See Box 11-A.

The terminally differentiated keratinocytes of the stratum corneum consist of flattened squames with a highly resistant compound cell envelope. Squames are sloughed from the surface of the epidermis and are continually replaced by keratinocytes of the inner strata.

Two additional characteristics of the epidermis are (1) the cell layer–specific expression of keratins observed during differentiation of keratinocytes (see Figure 11-5) and (2) the presence of tight junctions and desmosomes in the epidermis. The maintenance of a three-dimensional lattice of tightly attached keratinocytes is essential for the protective nature of the permeability barrier.

In Chapter 1, Epithelium, we discussed the structure and components of tight junctions, desmosomes, and intermediate filament keratins, including pathologic conditions such as blistering, epidermolytic, and proliferative diseases (Box 11-B).